Concord Biotech shares rise 6% after USFDA clears Mycophenolate Mofetil ANDA

Concord Biotech's stock gained 6 percent following regulatory news. The US Food and Drug Administration approved an ANDA for Mycophenolate Mofetil. The approval pertains to a generic version of the immunosuppressant drug. Business Standard reported the market reaction to the clearance. The decision enhances Concord Biotech's product portfolio. It may improve the company's revenue prospects. Investors welcomed the regulatory milestone. The firm is likely to monitor sales impact in the coming months.